Inovio Q2 Loss Narrows to $6M on Warrant Gain; FDA Decision Due Oct 30
INO sits 38% above its 52-week low of $0.563.
Summary
Inovio's Q2 net loss narrowed to $6.01M from a year earlier, helped by a $13.9M non-cash warrant liability gain and lower operating expenses of $18.62M. The company had no revenue in the quarter. Cash runway extends into late Q1 2027, including proceeds from the July offering. The FDA decision on INO-3107 is expected by October 30, 2026, with commercial preparations underway. This follows the 10-Q filed today that disclosed a going concern warning and the $18.3M July offering. The narrowed loss and regulatory timeline provide some clarity, but the going concern remains a key risk.
At the time of this announcement, INO was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.6M. The 52-week trading range was $0.56 to $2.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.